The injectable treatment Cimzia (certolizumab pegol) gets the go ahead from NICE, however Ilumetri (tildrakizumab) is not approved.
The National Institute for Health and Care Excellence (NICE) has published its initial decision to recommend the biologic treatment Cimzia (certolizumab pegol) as an option for treating severe psoriasis in adults in England and Wales, where the condition has not responded to other systemic therapies, or if these treatments are not suitable.
Cimzia blocks tumour necrosis factor-alpha (TNF alpha) a chemical ‘messenger’ in the immune system that signals other cells to cause inflammation. There is too much TNF alpha in the skin of people with psoriasis, which causes inflammation and can lead to tissue damage. TNF alpha can also lead to increased activity of the immune system by switching on certain white blood cells in the body, called T Cells. Once T cells become overactive they can trigger inflammation and other immune responses, encouraging the development of psoriasis.
Cimzia helps lower the amount of TNF alpha to more normal levels, and switches off the inflammatory cycle of psoriasis. This leads to improvement in symptoms for many people who take it.
We will be publishing more information on Cimzia (certolizumab pegol) for psoriasis soon. In the meantime, please get in touch with us if you have any questions.
Ilumetri (tildrakizumab) rejected by NICE
NICE has also published its decision not to recommend the biologic treatment Ilumetri (tildrakizumab) as an option for treating moderate to severe psoriasis after systemic therapy.